Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of DNA Repair02:25

Overview of DNA Repair

33.0K
In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...
33.0K
Overview of DNA Repair02:25

Overview of DNA Repair

9.2K
9.2K
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

4.6K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
4.6K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

40.1K
Overview
40.1K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.8K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.8K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.9K
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facing death: the last drawings of a woman with breast cancer at the end of life.

NPJ breast cancer·2026
Same author

Postbiotics in Dairy: A Comprehensive Review of Applications and Health Impacts.

Current nutrition reports·2026
Same author

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Immunotherapy·2026
Same author

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Current treatment options in oncology·2026
Same author

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same author

Post-Harvest UV-C Treatment of Microgreens for Inactivation of <i>Salmonella enterica</i>, <i>Escherichia coli</i> O157:H7 and <i>Listeria monocytogenes</i>.

Foods (Basel, Switzerland)·2026

Related Experiment Video

Updated: Dec 5, 2025

Visualizing and Quantifying Endonuclease-Based Site-Specific DNA Damage
10:59

Visualizing and Quantifying Endonuclease-Based Site-Specific DNA Damage

Published on: August 21, 2021

4.0K

The DNA damaging revolution.

Bulent Cetin1, Chiara A Wabl2, Ozge Gumusay2

  • 1Department of Internal Medicine, Division of Medical Oncology, Suleyman Demirel University, Faculty of Medicine, Isparta, Turkey.

Critical Reviews in Oncology/Hematology
|October 15, 2020
PubMed
Summary

Poly(ADP-ribose) polymerase (PARP) inhibitors show significant antitumor effects by creating synthetic lethality, particularly in BRCA-mutated cancers. Research is exploring their use across various tumor types and strategies to overcome treatment resistance.

Keywords:
BRCA mutationCombination therapyDNA damage responsePARP inhibitorsl

More Related Videos

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

11.6K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.6K

Related Experiment Videos

Last Updated: Dec 5, 2025

Visualizing and Quantifying Endonuclease-Based Site-Specific DNA Damage
10:59

Visualizing and Quantifying Endonuclease-Based Site-Specific DNA Damage

Published on: August 21, 2021

4.0K
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

11.6K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair pathways.
  • PARP inhibitors induce synthetic lethality, showing antitumor activity, especially in BRCA-mutated cancers.
  • PARP inhibitors like olaparib, veliparib, talazoparib, niraparib, and rucaparib are studied in breast and ovarian cancers.

Purpose of the Study:

  • To review the application of PARP inhibitors in diverse tumor types.
  • To explore strategies for overcoming resistance to PARP inhibitors.
  • To summarize ongoing clinical trials evaluating PARP inhibitors alone and in combination therapies.

Main Methods:

  • Literature review of PARP inhibitors in cancer therapy.
  • Analysis of clinical trial data for PARP inhibitors.
  • Summary of DNA damage response pathways and resistance mechanisms.

Main Results:

  • PARP inhibitors demonstrate significant single-agent antitumor activity.
  • Efficacy is pronounced in tumors with BRCA1/BRCA2 mutations.
  • Ongoing trials investigate combinations with other targeted therapies.

Conclusions:

  • PARP inhibitors are promising targeted therapies for specific cancer types.
  • Further research is needed to broaden their application and manage resistance.
  • Combination strategies hold potential for enhanced therapeutic outcomes.